FCS

EH Group Joins H2MARINE Project to Develop Next Generation Maritime Fuel Cells

Retrieved on: 
Thursday, February 29, 2024
Environmental Issues, Alternative Energy, Energy, Technology, Environment, Green Technology, Engineering, Maritime, Transport, Other Technology, Climate Change, Manufacturing, Hydrogen, EH, ZSW, Multimedia, DANA, FC, FCS, Entrepreneurship, Beyond Gravity, University, EPFL, VTT, University of Freiburg, ThyssenKrupp Marine Systems, PEM, Pressure, Renewable energy

EH Group is a proud member of H2MARINE, a co-funded initiative by the EU’s Clean Hydrogen Partnership and SERI (Switzerland).

Key Points: 
  • EH Group is a proud member of H2MARINE, a co-funded initiative by the EU’s Clean Hydrogen Partnership and SERI (Switzerland).
  • The project is committed to innovation in hydrogen technologies, focused on the development of next generation PEM fuel cell stacks for marine applications.
  • Based on its unique FC technology, EH Group will contribute its high power density stacks, further developed and optimised for marine use.
  • “Our high power density fuel cell technology has been recognised in its use for maritime applications, and we are delighted to contribute to its further development in this project.

Alivi Health Appoints Amanda Novak as Vice President of Business Development

Retrieved on: 
Tuesday, February 27, 2024
Health Insurance, Professional Services, Health, Insurance, Nitrile hydratase, Indiana University Bloomington, Transport, FCS, Culture, Growth, Indiana University, CHSA, WEX, Business development, Management

Alivi Health, a leading provider of transportation, card-based, and specialty benefits, is excited to announce the appointment of Amanda Novak as the newest addition to their team as Vice President of Business Development.

Key Points: 
  • Alivi Health, a leading provider of transportation, card-based, and specialty benefits, is excited to announce the appointment of Amanda Novak as the newest addition to their team as Vice President of Business Development.
  • With an impressive sales and business development background within the healthcare industry, Amanda brings a wealth of experience and expertise to the organization.
  • Before joining Alivi, Amanda was Vice President of Health Plan Sales with WEX, where she demonstrated exceptional leadership and strategic expertise.
  • Her track record includes spearheading successful initiatives and forging strong partnerships to drive business growth and revenue.

Florida Cancer Specialists & Research Institute Implements Contingency Plan to Overcome National Clearinghouse Outage

Retrieved on: 
Thursday, March 7, 2024
Pharmacy, FCS, Hospital, Physician, Change Healthcare, Safety, Hematology, NBC, Health, NBC News, Patient, News, Uncertainty, Senior counsel, The New York Times, Prescription, Insurance

FORT MYERS, Fla., March 7, 2024 /PRNewswire/ -- In the wake of the cyberattack and subsequent outage of Change Healthcare, Florida Cancer Specialists & Research Institute, LLC (FCS) stands resolute in its commitment to patient care and safety. Change Healthcare, the nation's largest clearinghouse for prescriptions, shut down its prescription processing system impacting over 900,000 physicians, 67,000 pharmacies, and 5,500 hospitals in the United States, including FCS and its medically integrated pharmacy, Rx To Go, LLC. Despite the challenges imposed by Change Healthcare's outage, the FCS and Rx To Go dedicated teams remained steadfast in delivering the highest standard of care to patients.

Key Points: 
  • FORT MYERS, Fla., March 7, 2024 /PRNewswire/ -- In the wake of the cyberattack and subsequent outage of Change Healthcare, Florida Cancer Specialists & Research Institute, LLC (FCS) stands resolute in its commitment to patient care and safety.
  • Florida Cancer Specialists & Research Institute and Rx To Go respond to Change Healthcare cyberattack and shutdown.
  • As FCS learned of the shutdown, a comprehensive contingency plan was put in place to ensure that patient care continues with minimal disruption.
  • To overcome the lasting effects from this attack on the medical community, it will require industry-wide collaborative efforts and interventions.

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

Retrieved on: 
Thursday, February 29, 2024
Allergy, Schering-Plough, FCS, AstraZeneca, King Pharmaceuticals, EVP, Hereditary angioedema, Ionis Pharmaceuticals, Acorda Therapeutics, Human, Therapy, IONS, Patient, Neurology, Pharmaceutical industry

CARLSBAD, Calif., Feb. 29, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company. Mr. Jenne has more than 25 years of biopharmaceutical commercial and executive leadership experience and has launched innovative medicines across a broad range of therapeutic areas including cardiovascular, neurology and allergy.

Key Points: 
  • Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.
  • She has built a stellar team of professionals with deep experience across all aspects of commercialization," said Brett P. Monia, Ionis' chief executive officer.
  • Mr. Jenne previously spent five years in commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020.
  • His most recent role at Ionis was as EVP & chief commercial officer.

Florida Cancer Specialists & Research Institute Expands Access To Cancer Care in Volusia County

Retrieved on: 
Tuesday, February 27, 2024
FCS, Volusia County, Florida, Physician, Golden Joystick Awards, Commerce, Central Florida, Administration, Patient, Cancer, Nursing

FORT MYERS, Fla., Feb. 27, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) has opened a new state-of-the-art facility at 2824 Enterprise Road, Orange City, FL 32763-8428 to provide comprehensive treatments and a variety of services to adults with cancer, blood disorders and other diseases. The new location, one of five FCS sites of service in Volusia County, replaces the former FCS clinic on Image Way.

Key Points: 
  • The new location, one of five FCS sites of service in Volusia County, replaces the former FCS clinic on Image Way.
  • "We are so proud of our rich history of providing world-class cancer care across Florida and driving the dramatic transformation of oncology care worldwide through our extensive clinical research program," said FCS President & Managing Physician Lucio N. Gordan, MD .
  • "Our patients are fortunate in that they have access to advanced treatment and state-of-the-art technology within each of our clinic locations."
  • Patients have in-house access to specialty pharmacy and hematopathology laboratory services, care coordination and clinical trial opportunities.

Jackson Honored for Creative and Effective Marketing and Communications Content in 2023

Retrieved on: 
Thursday, February 8, 2024
Professional Services, Marketing, Environmental, Social and Governance (ESG), Communications, Insurance, Finance, Banking, Communication, FCS, APEX, Jackson National Life, Retirement, Distribution, Biophysical environment, Organization, Growth, ESG, Senior, Publication, Stevie Awards, Environment, Social

The Distribution Marketing team at Jackson National Life Distributors LLC (JNLD), the marketing and distribution business of Jackson National Life Insurance Company ® (Jackson®)1, received several awards in 2023 showcasing the company’s marketing and creative services.

Key Points: 
  • The Distribution Marketing team at Jackson National Life Distributors LLC (JNLD), the marketing and distribution business of Jackson National Life Insurance Company ® (Jackson®)1, received several awards in 2023 showcasing the company’s marketing and creative services.
  • “At Jackson, we are committed to making retirement clearer for everyone.
  • In support of this, our team designs marketing collateral that is creative, informative and easy to understand, adding value to our relationships with our distribution partners.
  • The product kit system includes a variety of marketing pieces providing features and use cases for the range of products offered by Jackson.

CJ Biomaterials' Semi-Crystalline Polyhydroxyalkanoate (scPHA) Added to FDA's Inventory of Food Contact Substances

Retrieved on: 
Tuesday, January 30, 2024
FCN, Compost, Food, Agency, TUV, Biopolymer, Safety, FDA, FCS, PHA, Soil, CJ CheilJedang, Medical device

Company's scPHA can now be used in the manufacture of food contact materials sold in the U.S.

Key Points: 
  • Company's scPHA can now be used in the manufacture of food contact materials sold in the U.S.
    Second CJ Biomaterials biopolymer added to inventory, joining amorphous PHA
    Woburn, Massachusetts--(Newsfile Corp. - January 30, 2024) - CJ Biomaterials, Inc., a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, announced today that its semi-crystalline PHA (scPHA) biopolymer branded PHACT™ S1000P is now included in the U.S. Food and Drug Administration Inventory of Effective Food Contact Substances (FCS) with the Assigned Food Contact Notification (FCN) 2330.
  • Before being added to the FCS inventory, CJ Biomaterials' scPHA had to successfully complete extensive safety testing by the FDA.
  • "The addition of our PHACT S1000P technology to the FDA Inventory of Effective Food Contact Substances demonstrates CJ Biomaterials' commitment to safety and innovation," says Max Senechal, Chief Commercial Officer for CJ Biomaterials.
  • For more information on the advanced PHA technology being produced by CJ Biomaterials, and to contact them to partner on the development of sustainable solutions, visit https://cjbiomaterials.com/ .

Komet Sales Announces Merger with Axerrio

Retrieved on: 
Monday, January 29, 2024
Classification, ERP, Flower, Sale, FCS, Organization, Marketing, Plant, Atlantic Ocean, Bergen op Zoom, Growth, Online shopping

BERGEN OP ZOOM, NETHERLANDS, Jan 29, 2024 - (ACN Newswire) - Komet Sales and Axerrio have merged.

Key Points: 
  • BERGEN OP ZOOM, NETHERLANDS, Jan 29, 2024 - (ACN Newswire) - Komet Sales and Axerrio have merged.
  • Komet Sales ("Komet"), the leading software provider for the floral industry in North and South America, is pleased to announce the merger with Axerrio, a leading software provider for the floral industry in the Netherlands and Europe.
  • After the merger, the companies will work on a seamless integration between Axerrio and the Komet solutions.
  • Existing customers of both Komet Sales and Axerrio can expect a seamless transition and support.

Florida Cancer Specialists & Research Institute Best Practices Program Improves Treatment Response and Survival for Patients with Multiple Myeloma

Retrieved on: 
Thursday, January 25, 2024
Real-World Evidence, Death, Incidence, RN, BSN, Bachelor of Pharmacy, Partnership, Survival, RRMM, Multiple myeloma, CAPM, Bone marrow, Data, FDA, Current Oncology, FCS, Doctor of Philosophy, RPH, OCN, BP, Infrared spectroscopy correlation table, Immune system, Nursing

FORT MYERS, Fla., Jan. 25, 2024 /PRNewswire/ -- A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • A real-world study by FCS authors details a program to improve patient outcomes for multiple myeloma.
  • Results obtained from a one-year retrospective observational study using data collected by FCS' Real-World Evidence team were recently published in Current Oncology.
  • He added, "Our findings, as detailed in this article, support the hypothesis that a best practices program designed around specific anticancer drugs can optimize prescribing practices, leading to better disease control and improvements in a patient's cancer care journey."
  • The FCS Real-World Evidence team works with internal and external partners providing insights to improve treatment decisions and clinical outcomes based on evidence generated using real-world data.

Florida Cancer Specialists & Research Institute Innovations in Precision Oncology Informatics Showcased at World Conference

Retrieved on: 
Tuesday, January 23, 2024
Senior, NGS, Patient, MD, Precision, Conference, Data, FCS, Doctor of Philosophy, Biomarker, Informatics, Clinical trial, Medicine, Physician, Nursing

FORT MYERS, Fla., Jan. 23, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) Senior Vice President & Data Officer Trevor Heritage, PhD will share learnings gained from the statewide practice's development of an innovative propriety precision oncology platform at the Precision Medicine World Conference (PMWC® 2024) being held this month in Santa Clara, California. Dr. Heritage joins top global researchers and medical professionals across healthcare and biotechnology sectors at the three-day event, recognized as the foremost precision medicine conference.

Key Points: 
  • FORT MYERS, Fla., Jan. 23, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) Senior Vice President & Data Officer Trevor Heritage, PhD will share learnings gained from the statewide practice's development of an innovative propriety precision oncology platform at the Precision Medicine World Conference (PMWC® 2024) being held this month in Santa Clara, California.
  • Dr. Heritage joins top global researchers and medical professionals across healthcare and biotechnology sectors at the three-day event, recognized as the foremost precision medicine conference.
  • "FCS PRECISE™, our propriety precision oncology system, is critical in precision oncology decision-making, leading to optimal experiences and outcomes for our patients," said Dr. Heritage.
  • "I am delighted to join with other industry pioneers to help accelerate advances that will enable effective adoption of precision medicine in community oncology."